Patterns and predictors of substance use disorders and daily tobacco use in first-episode psychosis

References

• Drake R E, Brunette M F. Complications of severe mental illness related to alcohol and drug use disorders. Recent developments in alcoholism, volume 14: the consequences of alcoholism, M Galanter. Plenum, New York 1998; 285–299
   Google Scholar
• Ram R, Bromet E J, Eaton W W, Pato C, Schwartz J E. The natural course of schizophrenia: a review of first-admission studies. Schizophrenia Bulletin 1992; 18: 185–207
   PubMed Web of Science ®Google Scholar
• Edwards J, Hinton M, Elkins K, Athanasopoulos A. Cannabis and first-episode psychosis: the CAP project. Substance misuse in psychosis: approaches to treatment and service delivery, H Graham, K T Mueser, M Birchwood, A Copello. Wiley, Chichester 2003; 283–304
   Google Scholar
• Verma S K, Subramaniam M, Chong S, Kua E H. Substance abuse in schizophrenia: a Singapore perspective. Social Psychiatry and Psychiatric Epidemiology 2002; 37: 326–328
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Bromet E J, Carlson L G, Kovasznay B, Schwartz J E. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychological Medicine 1998; 28: 1411–1419
   PubMed Web of Science ®Google Scholar
• Hambrecht M, Hafner H. Substance abuse and the onset of schizophrenia. Biological Psychiatry 1996; 40: 1155–1163
   PubMed Web of Science ®Google Scholar
• Sevy S, Robinson D G, Solloway S, et al. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatric Scandinavica 2001; 104: 367–374
   PubMed Web of Science ®Google Scholar
• Cantwell R, Brewin J, Glazebrook C, et al. Prevalence of substance misuse in first-episode psychosis. British Journal of Psychiatry 1999; 174: 150–153
   PubMed Web of Science ®Google Scholar
• Linszen D H, Dingemans P M, Lenior M E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 1994; 51: 273–279
   PubMed Web of Science ®Google Scholar
• McGorry P D, Singh B S, Copolov D L, Kaplan I, Dossetor C R, van Riel R J. Royal Park Multidiagnostic Instrument for Psychosis: part II: development, reliability, and validity. Schizophrenia Bulletin 1990; 16: 517–536
   PubMed Web of Science ®Google Scholar
• McGovern M P, Morrison D H. The Chemical Use, Abuse, and Dependence scale (CUAD): rationale, reliability, and validity. Journal of Substance Abuse Treatment 1992; 9: 27–38
   PubMed Web of Science ®Google Scholar
• Kavanagh D J, Waghorn G, Jenner L, et al. Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophrenia Research 2004; 66: 115–124
   PubMed Web of Science ®Google Scholar
• Cannon-Spoor H E, Potkin S G, Wyatt R J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin 1982; 8: 470–484
   PubMed Web of Science ®Google Scholar
• Lukoff D, Liberman R P, Nuechterlein K H. Symptom monitoring in the rehabilitation of schizophrenic patients. Schizophrenia Bulletin 1986; 12: 578–602
   PubMed Web of Science ®Google Scholar
• Andreasen N C. Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, Iowa City 1981
   Google Scholar
• Hall W, Teesson M, Lynskey M, Degenhardt L. The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: findings from the National Survey of Mental Health and Well-Being. Addiction 1999; 94: 1541–1550
   PubMed Web of Science ®Google Scholar
• Blanchard J J, Brown S A, Horan W P, Sherwood A R. Substance use disorders in schizophrenia: review, integration, and a proposed model. Clinical Psychology Review 2000; 20: 207–234
   PubMed Web of Science ®Google Scholar
• Conus P, Lambert M, Eide P, et al. First episode outcome study (FEPOS study). Schizophrenia Research 2004; 67(Suppl)196
   Google Scholar
• Van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. Social Psychiatry and Psychiatric Epidemiology 2004; 39: 69–72
   PubMed Web of Science ®Google Scholar
• Morral A R, McCaffrey D F, Paddock S M. Reassessing the marijuana gateway effect. Addiction 2002; 97: 1493–1504
   PubMed Web of Science ®Google Scholar
• Arseneault L, Cannon M, Witton J, Murray R M. Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry 2004; 184: 110–117
   PubMed Web of Science ®Google Scholar
• Greenfield S F, Manwani S G, Nargiso J E. Epidemiology of substance use disorders in women. Obstetrics and Gynecology Clinics of North America 2003; 30: 413–446
   PubMed Web of Science ®Google Scholar
• Arndt S, Tyrrell G, Flaum M, Andreasen N C. Comorbidity of substance abuse and schizophrenia: the role of premorbid adjustment. Psychological Medicine 1992; 22: 379–388
   PubMed Web of Science ®Google Scholar
• Escobedo L G, Peddicord J P. Smoking prevalence in US birth cohorts: the influence of gender and education. American Journal of Public Health 1996; 86: 231–236
   PubMed Web of Science ®Google Scholar